Proteomic analysis of the human hippocampus identifies neuronal pentraxin 1 (NPTX1) as synapto-axonal target in late-stage Parkinson's disease.


Journal

Journal of neurochemistry
ISSN: 1471-4159
Titre abrégé: J Neurochem
Pays: England
ID NLM: 2985190R

Informations de publication

Date de publication:
09 2023
Historique:
revised: 06 07 2023
received: 01 03 2023
accepted: 17 07 2023
medline: 24 8 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: ppublish

Résumé

Parkinson's disease (PD) affects a significant proportion of the population over the age of 60 years, and its prevalence is increasing. While symptomatic treatment is available for motor symptoms of PD, non-motor complications such as dementia result in diminished life quality for patients and are far more difficult to treat. In this study, we analyzed PD-associated alterations in the hippocampus of PD patients, since this brain region is strongly affected by PD dementia. We focused on synapses, analyzing the proteome of post-mortal hippocampal tissue from 16 PD cases and 14 control subjects by mass spectrometry. Whole tissue lysates and synaptosomal fractions were analyzed in parallel. Differential analysis combined with bioinformatic network analyses identified neuronal pentraxin 1 (NPTX1) to be significantly dysregulated in PD and interacting with proteins of the synaptic compartment. Modulation of NPTX1 protein levels in primary hippocampal neuron cultures validated its role in synapse morphology. Our analysis suggests that NPTX1 contributes to synaptic pathology in late-stage PD and represents a putative target for novel therapeutic strategies.

Identifiants

pubmed: 37515330
doi: 10.1111/jnc.15924
doi:

Substances chimiques

neuronal pentraxin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

862-874

Informations de copyright

© 2023 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.

Références

Aarsland, D., Andersen, K., Larsen, J. P., & Lolk, A. (2003). Prevalence and characteristics of dementia in Parkinson disease: An 8-year prospective study. Archives of Neurology, 60(3), 387. https://doi.org/10.1001/archneur.60.3.387
Abad, M. A., Enguita, M., DeGregorio-Rocasolano, N., Ferrer, I., & Trullas, R. (2006). Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid- and is overexpressed in dystrophic neurites in Alzheimer's brain. Journal of Neuroscience, 26(49), 12735-12747. https://doi.org/10.1523/JNEUROSCI.0575-06.2006
Bellucci, A., Zaltieri, M., Navarria, L., Grigoletto, J., Missale, C., & Spano, P. (2012). From α-synuclein to synaptic dysfunctions: New insights into the pathophysiology of Parkinson's disease. Brain Research, 1476, 183-202. https://doi.org/10.1016/j.brainres.2012.04.014
Berg, D., Riess, O., & Bornemann, A. (2003). Specification of 14-3-3 proteins in Lewy bodies. Annals of Neurology, 54(1), 135. https://doi.org/10.1002/ana.10621
Braak, H., Del Tredici, K., Rüb, U., A I De Vos, R., Jansen Steur, E. N. H., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 24(2), 197-211. https://doi.org/10.1016/S0197-4580(02)00065-9
Caldi Gomes, L., Galhoz, A., Jain, G., Roser, A., Maass, F., Carboni, E., Barski, E., Lenz, C., Lohmann, K., Klein, C., Bähr, M., Fischer, A., Menden, M. P., & Lingor, P. (2022). Multi-omic landscaping of human midbrains identifies disease-relevant molecular targets and pathways in advanced-stage Parkinson's disease. Clinical and Translational Medicine, 12(1), e692. https://doi.org/10.1002/ctm2.692
Camicioli, R., Moore, M. M., Kinney, A., Corbridge, E., Glassberg, K., & Kaye, J. A. (2003). Parkinson's disease is associated with hippocampal atrophy. Movement Disorders, 18(7), 784-790. https://doi.org/10.1002/mds.10444
Cheng, H.-C., Ulane, C. M., & Burke, R. E. (2010). Clinical progression in Parkinson disease and the neurobiology of axons. Annals of Neurology, 67(6), 715-725. https://doi.org/10.1002/ana.21995
Cho, R. W., Park, J. M., Wolff, S. B. E., Xu, D., Hopf, C., Kim, J., Reddy, R. C., Petralia, R. S., Perin, M. S., Linden, D. J., & Worley, P. F. (2008). MGluR1/5-dependent long-term depression requires the regulated ectodomain cleavage of neuronal pentraxin NPR by TACE. Neuron, 57(6), 858-871. https://doi.org/10.1016/j.neuron.2008.01.010
Chung, C. Y., Koprich, J. B., Siddiqi, H., & Isacson, O. (2009). Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV -Synucleinopathy. Journal of Neuroscience, 29(11), 3365-3373. https://doi.org/10.1523/JNEUROSCI.5427-08.2009
Clayton, K. B., Podlesniy, P., Figueiro-Silva, J., López-Doménech, G., Benitez, L., Enguita, M., Abad, M. A., Soriano, E., & Trullas, R. (2012). NP1 regulates neuronal activity-dependent accumulation of BAX in mitochondria and mitochondrial dynamics. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 32(4), 1453-1466. https://doi.org/10.1523/JNEUROSCI.4604-11.2012
Compta, Y., & Revesz, T. (2021). Neuropathological and biomarker findings in Parkinson's disease and Alzheimer's disease: From protein aggregates to synaptic dysfunction. Journal of Parkinson's Disease, 11(1), 107-121. https://doi.org/10.3233/JPD-202323
Coutelier, M., Jacoupy, M., Janer, A., Renaud, F., Auger, N., Saripella, G.-V., Ancien, F., Pucci, F., Rooman, M., Gilis, D., Larivière, R., Sgarioto, N., Valter, R., Guillot-Noel, L., Le Ber, I., Sayah, S., Charles, P., Nümann, A., Pauly, M. G., … Stevanin, G. (2021). NPTX1 mutations trigger endoplasmic reticulum stress and cause autosomal dominant cerebellar ataxia. Brain: A Journal of Neurology, awab407, 1519-1534. https://doi.org/10.1093/brain/awab407
Cox, J., Michalski, A., & Mann, M. (2011). Software lock mass by two-dimensional minimization of peptide mass errors. Journal of the American Society for Mass Spectrometry, 22(8), 1373-1380. https://doi.org/10.1007/s13361-011-0142-8
Cummings, D. M., Benway, T. A., Ho, H., Tedoldi, A., Fernandes Freitas, M. M., Shahab, L., Murray, C. E., Richard-Loendt, A., Brandner, S., Lashley, T., Salih, D. A., & Edwards, F. A. (2017). Neuronal and peripheral pentraxins modify glutamate release and may interact in blood-brain barrier failure. Cerebral Cortex (New York, N.Y.: 1991), 27(6), 3437-3448. https://doi.org/10.1093/cercor/bhx046
DeGregorio-Rocasolano, N., Gasull, T., & Trullas, R. (2001). Overexpression of neuronal pentraxin 1 is involved in neuronal death evoked by low K+ in cerebellar granule cells. Journal of Biological Chemistry, 276(1), 796-803. https://doi.org/10.1074/jbc.M007967200
Deppe, J., Deininger, N., Lingor, P., Haack, T. B., Haslinger, B., & Deschauer, M. (2022). A novel NPTX1 de novo variant in a late-onset ataxia patient. Movement Disorders: Official Journal of the Movement Disorder Society, 37, 1319-1321. https://doi.org/10.1002/mds.28985
Dickson, D. W., Braak, H., Duda, J. E., Duyckaerts, C., Gasser, T., Halliday, G. M., Hardy, J., Leverenz, J. B., Del Tredici, K., Wszolek, Z. K., & Litvan, I. (2009). Neuropathological assessment of Parkinson's disease: Refining the diagnostic criteria. The Lancet Neurology, 8(12), 1150-1157. https://doi.org/10.1016/S1474-4422(09)70238-8
Duits, F. H., Brinkmalm, G., Teunissen, C. E., Brinkmalm, A., Scheltens, P., Van der Flier, W. M., Zetterberg, H., & Blennow, K. (2018). Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. Alzheimer's Research & Therapy, 10(1), 5. https://doi.org/10.1186/s13195-017-0335-x
Dulewicz, M., Kulczyńska-Przybik, A., Słowik, A., Borawska, R., & Mroczko, B. (2021). Neurogranin and neuronal pentraxin receptor as synaptic dysfunction biomarkers in Alzheimer's disease. Journal of Clinical Medicine, 10(19), 4575. https://doi.org/10.3390/jcm10194575
Esteve, A. S., Nilsson, J., Swift, I. J., Heller, C., Russell, L. L., Peakman, G., Convery, R. S., van Swieten, J. C., Seelaar, H., Borroni, B., Galimberti, D., Sanchez-Valle, R., Laforce, R., Moreno, F., Synofzik, M., Graff, C., Masellis, M., Tartaglia, M. C., Rowe, J. B., … GENetic FTD Initiative. (2021). Differential synaptic marker involvement in the different genetic forms of frontotemporal dementia. Alzheimer's & Dementia, 17(S5), e054934. https://doi.org/10.1002/alz.054934
Fard, M. K., van der Meer, F., Sánchez, P., Cantuti-Castelvetri, L., Mandad, S., Jäkel, S., Fornasiero, E. F., Schmitt, S., Ehrlich, M., Starost, L., Kuhlmann, T., Sergiou, C., Schultz, V., Wrzos, C., Brück, W., Urlaub, H., Dimou, L., Stadelmann, C., & Simons, M. (2017). BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions. Science Translational Medicine, 9(419), eaam7816. https://doi.org/10.1126/scitranslmed.aam7816
Figueiro-Silva, J., Gruart, A., Clayton, K. B., Podlesniy, P., Abad, M. A., Gasull, X., Delgado-García, J. M., & Trullas, R. (2015). Neuronal pentraxin 1 negatively regulates excitatory synapse density and synaptic plasticity. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 35(14), 5504-5521. https://doi.org/10.1523/JNEUROSCI.2548-14.2015
Goodman, A. R., Cardozo, T., Abagyan, R., Altmeyer, A., Wisniewski, H.-G., & Vilček, J. (1996). Long pentraxins: An emerging group of proteins with diverse functions. Cytokine & Growth Factor Reviews, 7(2), 191-202. https://doi.org/10.1016/1359-6101(96)00019-6
Higginbotham, L., Ping, L., Dammer, E. B., Duong, D. M., Zhou, M., Gearing, M., Hurst, C., Glass, J. D., Factor, S. A., Johnson, E. C. B., Hajjar, I., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2020). Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease. Science. Advances, 6(43), eaaz9360. https://doi.org/10.1126/sciadv.aaz9360
Hughes, C. S., Moggridge, S., Müller, T., Sorensen, P. H., Morin, G. B., & Krijgsveld, J. (2019). Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nature Protocols, 14(1), 68-85. https://doi.org/10.1038/s41596-018-0082-x
Johnson, E. C. B., Dammer, E. B., Duong, D. M., Ping, L., Zhou, M., Yin, L., Higginbotham, L. A., Guajardo, A., White, B., Troncoso, J. C., Thambisetty, M., Montine, T. J., Lee, E. B., Trojanowski, J. Q., Beach, T. G., Reiman, E. M., Haroutunian, V., Wang, M., Schadt, E., … Seyfried, N. T. (2020). Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nature Medicine, 26(5), 769-780. https://doi.org/10.1038/s41591-020-0815-6
Lambert, J.-P., Ivosev, G., Couzens, A. L., Larsen, B., Taipale, M., Lin, Z.-Y., Zhong, Q., Lindquist, S., Vidal, M., Aebersold, R., Pawson, T., Bonner, R., Tate, S., & Gingras, A.-C. (2013). Mapping differential interactomes by affinity purification coupled with data-independent mass spectrometry acquisition. Nature Methods, 10(12), 1239-1245. https://doi.org/10.1038/nmeth.2702
Langfelder, P., & Horvath, S. (2008). WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics, 9(1), 1-13.
Lee, S., Liu, H.-P., Lin, W.-Y., Guo, H., & Lu, B. (2010). LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the drosophila neuromuscular junction. Journal of Neuroscience, 30(50), 16959-16969. https://doi.org/10.1523/JNEUROSCI.1807-10.2010
Lerche, S., Sjödin, S., Brinkmalm, A., Blennow, K., Wurster, I., Roeben, B., Zimmermann, M., Hauser, A., Liepelt-Scarfone, I., Waniek, K., Lachmann, I., Gasser, T., Zetterberg, H., & Brockmann, K. (2021). Protein level of neurotransmitter secretion, synaptic plasticity, and autophagy in PD and DLB. Movement Disorders, 36(11), 2595-2604. https://doi.org/10.1002/mds.28704
Li, J., Sun, Y., & Chen, J. (2019). Transcriptome sequencing in a 6-hydroxydopamine rat model of Parkinson's disease. Genes & Genetic Systems, 94(2), 61-69. https://doi.org/10.1266/ggs.18-00036
Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z., & Zhang, B. (2019). WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Research, 47(W1), W199-W205. https://doi.org/10.1093/nar/gkz401
Licker, V., Turck, N., Kövari, E., Burkhardt, K., Côte, M., Surini-Demiri, M., Lobrinus, J. A., Sanchez, J.-C., & Burkhard, P. R. (2014). Proteomic analysis of human substantia nigra identifies novel candidates involved in Parkinson's disease pathogenesis. Proteomics, 14(6), 784-794. https://doi.org/10.1002/pmic.201300342
Lim, B., Sando, S. B., Grøntvedt, G. R., Bråthen, G., & Diamandis, E. P. (2020). Cerebrospinal fluid neuronal pentraxin receptor as a biomarker of long-term progression of Alzheimer's disease: A 24-month follow-up study. Neurobiology of Aging, 93, 97.e1-97.e7. https://doi.org/10.1016/j.neurobiolaging.2020.03.013
Lim, B., Tsolaki, M., Soosaipillai, A., Brown, M., Zilakaki, M., Tagaraki, F., Fotiou, D., Koutsouraki, E., Grosi, E., Prassas, I., & Diamandis, E. P. (2019). Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease. Clinical Chemistry and Laboratory Medicine (CCLM), 57(12), 1875-1881. https://doi.org/10.1515/cclm-2019-0428
Ma, Q.-L., Teng, E., Zuo, X., Jones, M., Teter, B., Zhao, E. Y., Zhu, C., Bilousova, T., Gylys, K. H., Apostolova, L. G., LaDu, M. J., Hossain, M. A., Frautschy, S. A., & Cole, G. M. (2018). Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease. Neurobiology of Disease, 114, 120-128. https://doi.org/10.1016/j.nbd.2018.02.014
Matta, S., Van Kolen, K., da Cunha, R., van den Bogaart, G., Mandemakers, W., Miskiewicz, K., De Bock, P.-J., Morais, V. A., Vilain, S., Haddad, D., Delbroek, L., Swerts, J., Chávez-Gutiérrez, L., Esposito, G., Daneels, G., Karran, E., Holt, M., Gevaert, K., Moechars, D. W., … Verstreken, P. (2012). LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron, 75(6), 1008-1021. https://doi.org/10.1016/j.neuron.2012.08.022
McKetney, J., Runde, R. M., Hebert, A. S., Salamat, S., Roy, S., & Coon, J. J. (2019). Proteomic atlas of the human brain in Alzheimer's disease. Journal of Proteome Research, 18(3), 1380-1391. https://doi.org/10.1021/acs.jproteome.9b00004
Moran, L. B., Hickey, L., Michael, G. J., Derkacs, M., Christian, L. M., Kalaitzakis, M. E., Pearce, R. K. B., & Graeber, M. B. (2008). Neuronal pentraxin II is highly upregulated in Parkinson's disease and a novel component of Lewy bodies. Acta Neuropathologica, 115(4), 471-478. https://doi.org/10.1007/s00401-007-0309-3
Muraoka, S., Jedrychowski, M. P., Yanamandra, K., Ikezu, S., Gygi, S. P., & Ikezu, T. (2020). Proteomic profiling of extracellular vesicles derived from cerebrospinal fluid of Alzheimer's disease patients: A pilot study. Cell, 9(9), 1959. https://doi.org/10.3390/cells9091959
Nägerl, U. V., Eberhorn, N., Cambridge, S. B., & Bonhoeffer, T. (2004). Bidirectional activity-dependent morphological plasticity in hippocampal neurons. Neuron, 44(5), 759-767. https://doi.org/10.1016/j.neuron.2004.11.016
Nilsson, J., Constantinescu, J., Nellgård, B., Jakobsson, P., Brum, W. S., Gobom, J., Forsgren, L., Dalla, K., Constantinescu, R., Zetterberg, H., Hansson, O., Blennow, K., Bäckström, D., & Brinkmalm, A. (2023). Cerebrospinal fluid biomarkers of synaptic dysfunction are altered in Parkinson's disease and related disorders. Movement Disorders, 38(2), 267-277. https://doi.org/10.1002/mds.29287
Ping, L., Duong, D. M., Yin, L., Gearing, M., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2018). Global quantitative analysis of the human brain proteome in Alzheimer's and Parkinson's disease. Scientific Data, 5(1), 180036. https://doi.org/10.1038/sdata.2018.36
Plotegher, N., Kumar, D., Tessari, I., Brucale, M., Munari, F., Tosatto, L., Belluzzi, E., Greggio, E., Bisaglia, M., Capaldi, S., Aioanei, D., Mammi, S., Monaco, H. L., Samo, B., & Bubacco, L. (2014). The chaperone-like protein 14-3-3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity. Human Molecular Genetics, 23(21), 5615-5629. https://doi.org/10.1093/hmg/ddu275
Riekkinen, P., Kejonen, K., Laakso, M. P., Soininen, H., Partanen, K., & Riekkinen, M. (1998). Hippocampal atrophy is related to impaired memory, but not frontal functions in non-demented Parkinsonʼs disease patients. Neuroreport, 9(7), 1507-1511. https://doi.org/10.1097/00001756-199805110-00048
Saal, K.-A., Galter, D., Roeber, S., Bähr, M., Tönges, L., & Lingor, P. (2017). Altered expression of growth associated Protein-43 and rho kinase in human patients with Parkinson's disease. Brain Pathology (Zurich, Switzerland), 27(1), 13-25. https://doi.org/10.1111/bpa.12346
Schirinzi, T., Madeo, G., Martella, G., Maltese, M., Picconi, B., Calabresi, P., & Pisani, A. (2016). Early synaptic dysfunction in Parkinson's disease: Insights from animal models: Early synaptic dysfunction in PD. Movement Disorders, 31(6), 802-813. https://doi.org/10.1002/mds.26620
Schlimgen, A. K., Helms, J. A., Vogel, H., & Perin, M. S. (1995). Neuronal pentraxin, a secreted protein with homology to acute phase proteins of the immune system. Neuron, 14(3), 519-526. https://doi.org/10.1016/0896-6273(95)90308-9
Seyfried, N. T., Dammer, E. B., Swarup, V., Nandakumar, D., Duong, D. M., Yin, L., Deng, Q., Nguyen, T., Hales, C. M., Wingo, T., Glass, J., Gearing, M., Thambisetty, M., Troncoso, J. C., Geschwind, D. H., Lah, J. J., & Levey, A. I. (2017). A multi-network approach identifies protein-specific Co-expression in asymptomatic and symptomatic Alzheimer nons disease. Cell Systems, 4(1), 60-72.e4. https://doi.org/10.1016/j.cels.2016.11.006
Shi, M., Jin, J., Wang, Y., Beyer, R. P., Kitsou, E., Albin, R. L., Gearing, M., Pan, C., & Zhang, J. (2008). Mortalin: A protein associated with progression of Parkinson disease? Journal of Neuropathology and Experimental Neurology, 67(2), 117-124. https://doi.org/10.1097/nen.0b013e318163354a
Sia, G.-M., Béïque, J.-C., Rumbaugh, G., Cho, R., Worley, P. F., & Huganir, R. L. (2007). Interaction of the N-terminal domain of the AMPA receptor GluR4 subunit with the neuronal pentraxin NP1 mediates GluR4 synaptic recruitment. Neuron, 55(1), 87-102. https://doi.org/10.1016/j.neuron.2007.06.020
Silbern, I., Fang, P., Ji, Y., Christof, L., Urlaub, H., & Pan, K.-T. (2021). Relative quantification of phosphorylated and glycosylated peptides from the same sample using isobaric chemical labelling with a two-step enrichment strategy. Methods in Molecular Biology (Clifton, N.J.), 2228, 185-203. https://doi.org/10.1007/978-1-0716-1024-4_14
Smyth, G. K., Ritchie, M., Thorne, N., & Wettenhall, J. (2005). LIMMA: Linear models for microarray data. In Bioinformatics and computational biology solutions using R and Bioconductor (pp. 397-420). New York: Springer. https://doi.org/10.1007/0-387-29362-0_23
Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., Jensen, L. J., & von Mering, C. (2019). STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Research, 47(D1), D607-D613. https://doi.org/10.1093/nar/gky1131
Tyanova, S., Temu, T., & Cox, J. (2016). The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nature Protocols, 11(12), 2301-2319. https://doi.org/10.1038/nprot.2016.136
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., Olsson, I., Edlund, K., Lundberg, E., Navani, S., Szigyarto, C. A.-K., Odeberg, J., Djureinovic, D., Takanen, J. O., Hober, S., … Pontén, F. (2015). Tissue-based map of the human proteome. Science, 347(6220), 1260419. https://doi.org/10.1126/science.1260419
van der Ende, E. L., Meeter, L. H., Stingl, C., van Rooij, J. G. J., Stoop, M. P., Nijholt, D. A. T., Sanchez-Valle, R., Graff, C., Öijerstedt, L., Grossman, M., McMillan, C., Pijnenburg, Y. A. L., Laforce, R., Binetti, G., Benussi, L., Ghidoni, R., Luider, T. M., Seelaar, H., & van Swieten, J. C. (2019). Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. Annals of Clinical and Translational Neurology, 6(4), 698-707. https://doi.org/10.1002/acn3.745
van der Ende, E. L., Xiao, M., Xu, D., Poos, J. M., Panman, J. L., Jiskoot, L. C., Meeter, L. H., Dopper, E. G., Papma, J. M., Heller, C., Convery, R., Moore, K., Bocchetta, M., Neason, M., Peakman, G., Cash, D. M., Teunissen, C. E., Graff, C., Synofzik, M., … van Swieten, J. C. (2020). Neuronal pentraxin 2: A synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery & Psychiatry, 91(6), 612-621. https://doi.org/10.1136/jnnp-2019-322493
Wang, Y., Yang, F., Gritsenko, M. A., Wang, Y., Clauss, T., Liu, T., Shen, Y., Monroe, M. E., Lopez-Ferrer, D., Reno, T., Moore, R. J., Klemke, R. L., Camp, D. G., & Smith, R. D. (2011). Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics, 11(10), 2019-2026. https://doi.org/10.1002/pmic.201000722
Xu, D., Hopf, C., Reddy, R., Cho, R. W., Guo, L., Lanahan, A., Petralia, R. S., Wenthold, R. J., O'Brien, R. J., & Worley, P. (2003). Narp and NP1 form heterocomplexes that function in developmental and activity-dependent synaptic plasticity. Neuron, 39(3), 513-528. https://doi.org/10.1016/S0896-6273(03)00463-X
Yuste, R., & Bonhoeffer, T. (2001). Morphological changes in dendritic spines associated with long-term synaptic plasticity. Annual Review of Neuroscience, 24, 1071-1089. https://doi.org/10.1146/annurev.neuro.24.1.1071
Yuzaki, M. (2018). Two classes of secreted synaptic organizers in the central nervous system. Annual Review of Physiology, 80, 243-262. https://doi.org/10.1146/annurev-physiol-021317-121322

Auteurs

Carmina C Warth Perez Arias (CC)

Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.
Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.
Collaborative Research Center 1286 "Quantitative Synaptology", University of Göttingen, Göttingen, Germany.

Ivan Silbern (I)

Collaborative Research Center 1286 "Quantitative Synaptology", University of Göttingen, Göttingen, Germany.
Bioanalytical Mass Spectrometry Group, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Bioanalytics Group, Department of Clinical Chemistry, University Medical Center Göttingen, Göttingen, Germany.

Lucas Caldi Gomes (L)

Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.
Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.
Clinical Department of Neurology, School of Medicine, rechts der Isar Hospital, Technical University of Munich, Munich, Germany.

Hannes Wartmann (H)

Institute for Medical Systems Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Vivian Dambeck (V)

Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.
Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.

Jonas Fanz (J)

Department of Neuropathology, University Medical Center Göttingen, Göttingen, Germany.
Göttingen Campus Institute for Dynamics of Biological Networks (CIDBN), University of Göttingen, Göttingen, Germany.

Lisa Neuenroth (L)

Bioanalytics Group, Department of Clinical Chemistry, University Medical Center Göttingen, Göttingen, Germany.

Mathias Bähr (M)

Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.
Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells" (MBExC), University of Göttingen, Göttingen, Germany.

Tiago F Outeiro (TF)

Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.
Max Planck Institute for Natural Sciences, Göttingen, Germany.
Faculty of Medical Sciences, Translational and Clinical Research Institute, Newcastle University, UK.
Scientific employee with an honorary contract at German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
Department of Experimental Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany.

Stefan Bonn (S)

Collaborative Research Center 1286 "Quantitative Synaptology", University of Göttingen, Göttingen, Germany.
Bioanalytical Mass Spectrometry Group, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Center for Biomedical AI, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Christine Stadelmann-Nessler (C)

Department of Neuropathology, University Medical Center Göttingen, Göttingen, Germany.

Silvio O Rizzoli (SO)

Center for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.
Collaborative Research Center 1286 "Quantitative Synaptology", University of Göttingen, Göttingen, Germany.
Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells" (MBExC), University of Göttingen, Göttingen, Germany.
Department for Neuro- and Sensory Physiology, University Medical Center Göttingen, Göttingen, Germany.

Christof Lenz (C)

Collaborative Research Center 1286 "Quantitative Synaptology", University of Göttingen, Göttingen, Germany.
Bioanalytical Mass Spectrometry Group, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Bioanalytics Group, Department of Clinical Chemistry, University Medical Center Göttingen, Göttingen, Germany.

Henning Urlaub (H)

Collaborative Research Center 1286 "Quantitative Synaptology", University of Göttingen, Göttingen, Germany.
Bioanalytical Mass Spectrometry Group, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells" (MBExC), University of Göttingen, Göttingen, Germany.
Department of Clinical Chemistry, University Medical Center Göttingen, Göttingen, Germany.

Paul Lingor (P)

Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.
Collaborative Research Center 1286 "Quantitative Synaptology", University of Göttingen, Göttingen, Germany.
Clinical Department of Neurology, School of Medicine, rechts der Isar Hospital, Technical University of Munich, Munich, Germany.
German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH